Tagworks

Tagworks Pharmaceuticals is a precision oncology company and pioneer of Click-to-Release technology — a proprietary in vivo click chemistry platform that enables controlled, on-target drug release to increase therapeutic efficacy while reducing systemic toxicity. The platform has broad applicability across multiple systemic treatment modalities, including antibody-drug conjugates (ADCs), immunomodulators, and radiopharmaceuticals. Tagworks' lead program, TGW101, is a first-in-class click-cleavable ADC targeting TAG-72, a non-internalizing receptor widely expressed in solid tumors that has historically been inaccessible to conventional ADC therapies. A second program, TGW211, is a HER2-directed radioimmunoconjugate in Phase 0/1 clinical trials. Headquartered in Nijmegen, the Netherlands, the company is led by a team of researchers, oncologists, and biotech executives.